Abstract:Atherosclerosis research typically focuses on the evolution of intermediate or advanced atherosclerotic lesions rather than on prelesional stages of atherogenesis. Yet these early events may provide decisive leads on the triggers of the pathologic process, before lesions become clinically overt. Thereby, it is mandatory to consider extracellular lipoprotein deposition at this stage as the prerequisite of foam cell formation leading to a remarkable accumulation of LDL (Low Density Lipoproteins). As progression of atherosclerosis displays the characteristic features of a chronic inflammatory process on the one hand and native LDL lacks inflammatory properties on the other hand, the lipoprotein must undergo biochemical modification to become atherogenic. During the last 25 years, evidence was accumulated in support of a different concept on atherogenesis proposing that modification of native LDL occurs through the action of ubiquitous hydrolytic enzymes (enzymatically modified LDL or eLDL) rather than oxidation and contending that the physiological events leading to macrophage uptake and reverse transport of eLDL first occur without inflammation (initiation with reversion). Preventing or reversing initial atherosclerotic lesions would avoid the later stages and therefore prevent clinical manifestations. This concept is in accordance with the response to retention hypothesis directly supporting the strategy of lowering plasma levels of atherogenic lipoproteins as the most successful therapy for atherosclerosis and its sequelae. Apart from but unquestionable closely related to this concept, there are several other hypotheses on atherosclerotic lesion initiation favoring an initiating role of the immune system ('vascular-associated lymphoid tissue' (VALT)), defining foam cell formation as a variant of lysosomal storage disease, relating to the concept of the inflammasome with crystalline cholesterol and/or mitochondrial DAMPs (damage-associated molecular patterns) being mandatory in driving arterial inflammation and, last but not least, pointing to miRNAs (micro RNAs) as pivotal players. However, direct anti-inflammatory therapies may prove successful as adjuvant components but will likely never be used in the absence of strategies to lower plasma levels of atherogenic lipoproteins, the key point of the perception that atherosclerosis is not simply an inevitable result of senescence. In particular, given the importance of chemical modifications for lipoprotein atherogenicity, regulation of the enzymes involved might be a tempting target for pharmacological research.

Involvement of Lipids and Lipid Mediators in Inflammation and Atherogenesis

Role of Lipid Accumulation and Inflammation in Atherosclerosis: Focus on Molecular and Cellular Mechanisms

Moving from lipids to leukocytes: inflammation and immune cells in atherosclerosis

Hegemony of inflammation in atherosclerosis and coronary artery disease

The immune system in atherosclerosis

Atherosclerosis: cell biology and lipoproteins--new mechanistic links in atherosclerosis: chemokines mediating the effects of lipids, platelets and dendritic cells.

The cellular biology of atherosclerosis with atherosclerotic lesion classification and biomarkers

Atherosclerosis: Beyond the lipid storage hypothesis. The role of autoimmunity

The Initial Human Atherosclerotic Lesion and Lipoprotein Modification-A Deep Connection

Role of Mast Cells in Atherosclerosis: A Classical Inflammatory Disease

New Insights into the Role of Inflammation in the Pathogenesis of Atherosclerosis

Innate Immune Pathways in Atherosclerosis—From Signaling to Long-Term Epigenetic Reprogramming

Cytokines and atherosclerosis: a comprehensive review of studies in mice

Inflammation during the life cycle of the atherosclerotic plaque

Immune-Inflammatory Responses in Atherosclerosis: The Role of Myeloid Cells

Inflammation and Thrombosis in Coronary Atherosclerosis: Pathophysiologic Mechanisms and Clinical Correlations

Adhesion Molecules and Atherogenesis

Inflammation in atherosclerosis: pathophysiology and mechanisms

Participation of Krüppel-like Factors in Atherogenesis

Molecular and cellular mechanisms of inflammation in atherosclerosis

The Role of Cytokines in Cholesterol Accumulation in Cells and Atherosclerosis Progression